Oramed pivots from pharma R&D to medical-tech operator; spins out oral insulin IP to Lifeward

Filed May 19, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 15, 2025 · ~2 min read

Key Changes

• high

  Company fundamentally redefined itself from oral insulin developer to strategic operator acquiring controlling stakes in medical technology businesses, appointing management and directing clinical trials rather than conducting internal R&D.

  MD&A: Business Model verify on EDGAR →
• high

  Transferred core POD oral insulin technology and $6.5M to OraTech subsidiary, then sold OraTech to Lifeward for 1.25M shares, 1M pre-funded warrants, 1.3M purchase warrants, and 4% revenue share on ReWalk products; R&D expenses now borne by OraTech.

  MD&A: Lifeward Transaction verify on EDGAR →
• high

  Invested $36.9M in Alpha Tau (17% stake, two board seats) for alpha-radiation cancer therapy platform with five concurrent FDA trials and Japan regulatory approval; company now provides investor relations services under $3M agreement.

  MD&A: Alpha Tau Investment verify on EDGAR →